Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study
Open Access
- 5 August 2026
- journal article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 1956-1966
Abstract
Aims: Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear. Materials and Methods: This 24‐week, prospective, randomized, open‐label, multicenter exploratory trial was conducted in Japan. Hypertensive patients with type 2 diabetes mellitus and albuminuria receiving standard‐dose angiotensin II receptor blocker therapy were randomized to angiotensin II receptor blocker dose escalation or esaxerenone add‐on therapy. Of 50 randomized patients, 47 were included in the full analysis set and 39 in the final analysis population (20 in the angiotensin II receptor blocker dose‐escalation group and 19 in the esaxerenone add‐on group). The primary endpoints were changes from baseline to Week 24 in urinary albumin‐to‐creatinine ratio and oxidative stress assessed by diacron‐reactive oxygen metabolites. Results: Esaxerenone add‐on therapy produced a significantly greater reduction in log‐transformed urinary albumin‐to‐creatinine ratio than angiotensin II receptor blocker dose‐escalation therapy, with an adjusted between‐group ratio of 0.71 (95% confidence interval, 0.58–0.87; p = 0.002). Systolic and diastolic blood pressures were significantly lower with esaxerenone. Estimated glomerular filtration rate decreased more with esaxerenone, whereas serum potassium levels did not differ significantly between groups. No significant between‐group difference was observed in diacron‐reactive oxygen metabolites. Conclusions: In hypertensive patients with type 2 diabetes mellitus and albuminuria, esaxerenone add‐on therapy reduced albuminuria and blood pressure more effectively than angiotensin II receptor blocker dose escalation but did not significantly reduce oxidative stress.Keywords
This publication has 26 references indexed in Scilit:
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III studyClinical and Experimental Nephrology, 2021
- Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 DiabetesDiabetes Therapy, 2021
- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studiesThe Lancet Diabetes & Endocrinology, 2019
- Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetesDiabetes Research and Clinical Practice, 2018
- Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetesDiabetes Research and Clinical Practice, 2016
- Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end productsImmunology Letters, 2015
- Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant dataThe Lancet Diabetes & Endocrinology, 2015
- Glycemic Control and Complications in Type 2 Diabetes MellitusThe American Journal of Medicine, 2010
- Pathogenesis, prevention, and treatment of diabetic nephropathyThe Lancet, 1998